
"I am glad that taking part in a trial might help others on their own cancer journey.”
This trial compared a chemotherapy drug called azacitidine with the usual treatment for older people with acute myeloid leukaemia (AML).
Doctors usually treat AML with chemotherapy. To get rid of the AML they can use chemotherapy drugs such as cytarabine and daunorubicin.
This does not always work for older people (over the age of 65) with AML. So doctors are looking for ways to improve treatment for this group of people.
The researchers thought that another low intensity chemotherapy drug called azacitidine could work better.
The aims of this trial were to
The trial team found that azacitidine could be a useful treatment for older people with AML and the side effects were similar to the usual treatments.
488 people age 65 and over took part. Of those,
o Cytarabine and daunorubicin or idarubicin and best supportive care
o Low dose cytarabine and best supportive care
o Best supportive care
Best supportive care means treatment to help with symptoms or side effects of any leukaemia treatment. This could include
The trial team looked at how long people lived for after treatment. They found this was on average
The most common side effects of azacitidine were
People in the usual treatment groups had similar side effects, apart from the people who had best supportive care alone. They had the fewest side effects.
The trial team suggest that azacitidine is a useful and safe treatment for older patients with newly diagnosed AML.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Michael Potter
Celgene Ltd
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”